Nanogen and Transgenomic in Distribution Agreement
By HospiMedica staff writers
Posted on 30 Jan 2004
A distribution agreement has been announced by Nanogen, Inc. (San Diego, CA, USA) and Transgenomic, Inc. (Omaha, NE, USA) that will allow Transgenomic to distribute Nanogen's NanoChip Molecular Biology Workstation in selected western European countries.Posted on 30 Jan 2004
The NanoChip Workstation is an automated, open-architecture instrument that facilitates routine detection of known genetic variations, such as single nucleotide polymorphisms (SNPs) and short tandem repeats (STRs), complementing the Transgenomic Wave system's ability to scan for unknown genetic variations. The Wave technology has proven highly effective in detecting low-abundance genetic variation, such as somatic mutations that may arise during the course of cancer progression or in the development of drug resistance. The Wave systems have broad applicability to genetic research and molecular diagnostics. More than 1,000 systems have been installed around the world.
"This agreement is part of a strategy of providing total complementary solutions for the genetic research and clinical laboratory markets in Europe,” noted Collin D'Silva, CEO of Transgenomic. "We foresee significant synergy from the addition of the Nanogen platform to our well-established European marketing efforts.”
Related Links:
Nanogen
Transgenomic
New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
New
Sample Transportation System
Tempus1800 Necto
New
 (3) (1).png){kind=logo}
Pipette
Accumax Smart Series
